Are Biosimilars fast becoming the same as pharmaceutical generics; lowest cost and lowest price wins? Is there really a benefit to copying a sponsor’s biological product or are there other ways to fast track FDA approval of your competitive biological product without the need to engage in the Biosimilar dance?